| Field | Specification |
|---|---|
| Mfr No | |
| Cas No. | |
| Clonality | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
lotivibart (VK645036) is a research-grade recombinant antibody targeting gp120/Glycoprotein 120. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
Specifications
| Host Species | Human |
|---|---|
| Species Reactivity | Human immunodeficiency virus 1 (HIV-1) |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | gp120/Glycoprotein 120 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| UniProt | Q03805 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Envelope glycoprotein gp160 (gp120/Glycoprotein 120) is a ~96 kDa protein. Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
Reactivity
This antibody shows reactivity with Human immunodeficiency virus 1 (HIV-1).
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
